Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention

National Institute for Health and Clinical Excellence

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors’ conclusions
Prasugrel in combination with aspirin is recommended as an option for preventing atherothrombotic events in people with acute coronary syndromes having percutaneous coronary intervention, only when:
• immediate primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction is necessary or
• stent thrombosis has occurred during clopidogrel treatment or
• the patient has diabetes mellitus.
People currently receiving prasugrel for treatment of acute coronary syndromes whose circumstances do not meet the criteria above should have the option to continue therapy until they and their clinicians consider it appropriate to stop.

Project page URL

Final publication URL
http://www.nice.org.uk/TA182

PubMedID
20801857

Indexing Status
Subject indexing assigned by NLM

MeSH
Acute Coronary Syndrome /economics /therapy; Angioplasty, Balloon, Coronary; Cost-Benefit Analysis; Evidence-Based Medicine /methodss; Piperazines /therapeutic use; Platelet Aggregation Inhibitors /therapeutic use; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes /therapeutic use

Language Published
English

Country of organisation
England

Address for correspondence
National Institute for Health and Clinical Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA, UK Tel: +44 020 7067 5800; Fax: +44 020 7067 5801 Email: nice@nice.nhs.uk

AccessionNumber
32011000084
Date abstract record published
26/01/2011